drugset / Trial / NCT01908894
Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration
RandomizedCrossoverDouble-blindTreatment
Summary
The primary objective is to assess the speed of absorption of BIOD-123 and BIOD-125 and compare them to Humalog.
Timeline
- Start
- 2012-02
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIOD-123 | Unknown | 0.2 iu/kg | Subcutaneous |
| Subject | BIOD-125 | Unknown | 0.2 iu/kg | Subcutaneous |
| Comparator | Insulin Lispro | Protein / enzyme biologic | 0.2 iu/kg | Subcutaneous |